Delcath Systems, Inc. is an interventional oncology company that develops and commercializes proprietary products for the treatment of primary and metastatic liver cancers. Its key offerings include the HEPZATO KIT™ (melphalan) for Injection and the CHEMOSAT® Hepatic Delivery System, which utilize a specialized procedure for hepatic delivery of chemotherapy. The company focuses on providing targeted therapies that enhance clinical outcomes while minimizing drug-related side effects, primarily serving patients with liver cancer across various geographies.
- Website
- www.delcath.com
- Issuer profile
- All listings